Lindbrook Capital, LLC Pro Qr Therapeutics N.V. Transaction History

Lindbrook Capital, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 21, 2022	SELL	$0.9 - $8.39 $1,822 - $16,989	-2,025 Closed	0 $0
Q4 2021 Jan 18, 2022	SELL	$6.58 - $8.44 $94,166 - $120,784	-14,311 Reduced 87.6%	2,025 $16,000
Q3 2021 Nov 05, 2021	BUY	$5.16 - $8.47 $19,277 - $31,643	3,736 Added 29.65%	16,336 $137,000
Q2 2021 Jul 27, 2021	BUY	$5.75 - $7.59 $17,250 - $22,770	3,000 Added 31.25%	12,600 $85,000
Q1 2021 Apr 28, 2021	BUY	$4.14 - $9.22 $37,260 - $82,980	9,000 Added 1500.0%	9,600 $63,000
Q3 2020 Nov 03, 2020	SELL	$4.79 - $6.3 $3,266 - $4,296	-682 Reduced 53.2%	600 $3,000
Q2 2020 Jul 27, 2020	BUY	$4.5 - $6.53 $2,002 - $2,905	445 Added 53.17%	1,282 $8,000
Q1 2020 Apr 22, 2020	SELL	$5.25 - $9.9 $2,955 - $5,573	-563 Reduced 40.21%	837 $5,000
Q4 2019 Jan 27, 2020	BUY	$5.84 - $10.51 $4,672 - $8,408	800 Added 133.33%	1,400 $14,000
Q3 2019 Oct 31, 2019	BUY	$5.76 - $9.44 $1,728 - $2,832	300 Added 100.0%	600 $3,000
Q1 2019 Apr 23, 2019	SELL	$12.5 - $18.48 $16,250 - $24,024	-1,300 Reduced 81.25%	300 $4,000
Q4 2018 Feb 07, 2019	BUY	$15.25 - $22.4 $24,400 - $35,840	1,600 New	1,600 $25,000

17.4M

37.7K

21.3K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $191M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.